Efficacy Study of Mupirocin on Infection After Coronary Artery Bypass Grafting
Information source: Horizon Health Network
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Surgical Site Infections
Intervention: Mupirocin (Drug)
Phase: Phase 3
Status: Completed
Sponsored by: Horizon Health Network Official(s) and/or principal investigator(s): Craig D Brown, BSc (Med), MD, FRCSC, FACS, Principal Investigator, Affiliation: New Brunswick Heart Centre
Summary
The hypothesis is that application of Mupirocin to the nose before and after coronary artery
bypass grafting surgery will reduce the incidence of surgical site infections.
Clinical Details
Official title: MIR-CABG: A Randomized, Double-blind, Placebo-controlled, Single-Center Study to Evaluate the Impact of Mupirocin on Infection Rate Post Coronary Artery Bypass Grafting
Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention
Primary outcome: Surgical Site Infection
Secondary outcome: MortalitySerious adverse durg effects S. aureus carrier status
Detailed description:
Mupirocin applied to the nares is effective in eradicating nasal carriage of Staphylococcus
species. Abundant evidence has documented that a majority of gram positive surgical site
infections share bacterial phenotypes identical with nasal phage types. Conflicting
literature exists regarding the efficacy of mupirocin in reducing the incidence of surgical
site infections. A randomized prospective double-blind placebo-controlled trial is needed
to help settle this question in the setting of coronary artery bypass grafting surgery where
surgical site infections carry significant morbidity, cost, and mortality.
Eligibility
Minimum age: 19 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Adults >18 years old undergoing Coronary Artery Bypass Grafting Surgery (CABG) with
or without concomitant cardiac valve surgery or other cardiac surgery,
- Median sternotomy wound
- Capable of informed consent
Exclusion Criteria:
- Allergy to mupirocin or components
- Pregnant or lactating females
- Emergency surgery
- Pre-existing ongoing infection
Locations and Contacts
New Brunswick Heart Centre, Saint John Regional Hospital, Saint John, New Brunswick E2L 4L2, Canada
Additional Information
Starting date: March 2009
Last updated: September 20, 2013
|